期刊文献+

糖尿病的口服降糖药物治疗

Orally-taken Medicine for DM
下载PDF
导出
摘要 目的 :分类介绍糖尿病的口服降糖药物 ,指导临床上正确应用及合理的个性化选择 ;方法 :基础理论研究及临床实践观察 ;结果 :随着糖尿病基础理论研究的深入及临床药理学的迅速发展 ,口服降糖药物的研究与开发取得了很大进展 ,新药相继问世 ,为糖尿病的防治拓展了更加广阔的空间 ;结论 :口服降糖药物种类繁多 ,进行正确应用及合理的个体化选择是促进糖尿病防治水平提高的关键。 Objective:Respective introduction to the orally-taken medicine for DM,Instructions for properly using the medicine and take choice of medicine according to patien's situation;Methods:Combined basic theory research and practical observation during the clinical treatment;Results:With the development of basic theory research on DM and also the rapid development of clinical pharmacology,many new kinds of medicine comes out one after anothe,which provides more ways to cure the DM;Conclusion:Properly using and choosing medicine form the variety is very vital for improving our prevention and treatment to DM.
出处 《内蒙古医学杂志》 2003年第1期54-57,共4页 Inner Mongolia Medical Journal
关键词 糖尿病 降糖药 治疗 磺脲类 双胍类 Α-糖苷酶抑制剂 胰岛素促分泌物 胰岛素增敏剂 Diabetes mellitus Sulfonylura agents Biguanide agents α-glulosidase inhibitor Insulin promoter Thiazolidinediones
  • 相关文献

参考文献8

  • 1郭连宇.治疗糖尿病药物的新进展[J].国外医学(内分泌学分册),1998,18(2):98-101. 被引量:9
  • 2陈亮,杨华章.糖尿病口服药物治疗进展[J].国外医学(内分泌学分册),2000,20(3):140-143. 被引量:26
  • 3谢燕,顾振纶,王殿彬.曲格列酮在糖尿病治疗中的应用[J].国外医学(内分泌学分册),1999,19(4):183-184. 被引量:2
  • 4Foley JE. Rationale and application of fatty acid oxidation inhibitots in treatment of diabetes meclitus[J]. Diabetes Care, 1992,15 :773.
  • 5Stscpoole PW, Greene YJ. Dichloracetate [ J ] . Diabetes Care,1992,15:785.
  • 6Douchert P, Verma S, Grynpas MD, et al. Vanadium and diabetes[ J ]. Mol Cell Biochem, 1998,188:73.
  • 7U. S Department of Health and Human Services. Cardiac Valvulopathy associated with exposure to fenfluramine or dexfenfluramine[ J ]. MMWR, 1997,46:1061.
  • 8Vray M, Attali JR. Randomized study of glibenclamide versus traditional Chinese treatment in type Z diabetic patients Chinese French Scientific committee for the Sutdy of Diabetes[ J ] .Diabet Metab, 1995,21:433.

二级参考文献15

  • 1Owens DR.Repaglinide-prandialglucose regulator:a new class of oral antidiabetic drugs 〔J〕.Diabet Med,1998,15(Supp14):S28~S36.
  • 2John R.White Jr,Pharm D.The Pharmacological reduction of blood glucose in patientswith type 2 diabetes mellitus 〔J〕.Clin Diabet,1998,16:2~4.
  • 3BalfourJA,FauldsD.Repaglinide〔J〕.DrugsAging,1998,13:173-180.
  • 4Lefebvre PJ,Scheen AJ.The postprandial state risk of cardiovascular disease 〔J〕.DiabetMed,1998,15(Supp1 4):S63~S68.
  • 5Hatorp V,Huang WC,Strange P.Pharmacokinetic profiles of repaglinide in elderlysubjects with type 2 diabetes 〔J〕.J Clin Endocrinol Metab,1999,84:1475~1478.
  • 6Hatorp V,Oliver S,Su CA.Biavailability of repaglinide,a novel antidiabeticagent,administered orally in tablet or solution form or intravenously in healthy malevolunteers 〔J〕.Int J Clin Pharmacol Ther,1998,36:636~641.
  • 7Chetty DJ,Chien YW.Novel methods of insulin delivery:an update 〔J〕.Crit RevTher Drug Carrier Syst,1998,15:629~670.
  • 8Saudek CD.Novel forms of insulin delivery 〔J〕.Endocrinol Metab Clin NorthAm,1997,26:599~610.
  • 9Kimura T,Sato K,Sugimoto K,et al.Oral administration of insulin as poly (vinylalcohol)-gel spheres in diabetic rats 〔J〕.Biol Pharm Bull,1996,19:897~900.
  • 10Foley JE.Rationale and application of fatty acid oxidation inhibitors in treatmentof diabetes mellitus 〔J〕.Diabetes Care,1992,15:773~784.

共引文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部